Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Substrate binding to Src: a new perspective on tyrosine kinase substrate recognition from NMR and molecular dynamics.

Joshi MK, Burton RA, Wu H, Lipchik AM, Craddock BP, Mo H, Parker LL, Miller WT, Post CB.

Protein Sci. 2019 Nov 7. doi: 10.1002/pro.3777. [Epub ahead of print]

PMID:
31697410
2.

Assays for tyrosine phosphorylation in human cells.

Kruk M, Widstrom N, Jena S, Wolter NL, Blankenhorn JF, Abdalla I, Yang TY, Parker LL.

Methods Enzymol. 2019;626:375-406. doi: 10.1016/bs.mie.2019.06.026. Epub 2019 Jul 24.

PMID:
31606083
3.

The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.

Moreno NS, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA.

Nucleic Acids Res. 2019 Nov 4;47(19):10475. doi: 10.1093/nar/gkz802. No abstract available.

4.

The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.

Salvador Moreno N, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA.

Nucleic Acids Res. 2019 Apr 8;47(6):2703-2715. doi: 10.1093/nar/gkz138.

5.

A Gradient in Metaphase Tension Leads to a Scaled Cellular Response in Mitosis.

Mukherjee S, Sandri BJ, Tank D, McClellan M, Harasymiw LA, Yang Q, Parker LL, Gardner MK.

Dev Cell. 2019 Apr 8;49(1):63-76.e10. doi: 10.1016/j.devcel.2019.01.018. Epub 2019 Feb 21.

PMID:
30799228
6.

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

Noel BM, Ouellette SB, Marholz L, Dickey D, Navis C, Yang TY, Nguyen V, Parker SJ, Bernlohr D, Sachs Z, Parker LL.

J Proteome Res. 2019 Apr 5;18(4):1842-1856. doi: 10.1021/acs.jproteome.9b00028. Epub 2019 Feb 21.

PMID:
30730747
7.

High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive In Vitro Kinase Assay Substrates.

Perez M, Blankenhorn J, Murray KJ, Parker LL.

Mol Cell Proteomics. 2019 Mar;18(3):477-489. doi: 10.1074/mcp.RA118.001111. Epub 2018 Dec 12.

PMID:
30541869
8.

Research Apprenticeship and Its Potential as a Distinct Model of Peer Research Practice.

Arrieta MI, Wells NK, Parker LL, Hudson AL, Crook ED.

Prog Community Health Partnersh. 2018;12(2):199-214. doi: 10.1353/cpr.2018.0040.

9.

In Silico Design and in Vitro Characterization of Universal Tyrosine Kinase Peptide Substrates.

Marholz LJ, Zeringo NA, Lou HJ, Turk BE, Parker LL.

Biochemistry. 2018 Mar 27;57(12):1847-1851. doi: 10.1021/acs.biochem.8b00044. Epub 2018 Mar 12.

10.

N6-methyladenine is an epigenetic marker of mammalian early life stress.

Kigar SL, Chang L, Guerrero CR, Sehring JR, Cuarenta A, Parker LL, Bakshi VP, Auger AP.

Sci Rep. 2017 Dec 22;7(1):18078. doi: 10.1038/s41598-017-18414-7.

11.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA.

J Clin Oncol. 2017 Oct 10;35(29):3322-3329. doi: 10.1200/JCO.2017.74.5463. Epub 2017 Aug 15.

12.

Consolidating the Academic End of a Community-Based Participatory Research Venture to Address Health Disparities.

Arrieta MI, Fisher L, Shaw T, Bryan V, Hudson A, Hansberry S, Eastburn S, Freed CR, Shelley-Tremblay S, Hanks RS, Washington-Lewis C, Roussel L, Dagenais PA, Icenogle M, Slagle ML, Parker LL, Crook E.

J High Educ Outreach Engagem. 2017;21(3):113-134.

13.

A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance.

Ouellette SB, Noel BM, Parker LL.

PLoS One. 2016 Sep 6;11(9):e0161748. doi: 10.1371/journal.pone.0161748. eCollection 2016.

14.
15.

Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.

Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF.

J Immunother. 2016 Jun;39(5):191-201. doi: 10.1097/CJI.0000000000000123.

16.

Time-Resolved Proteomic Visualization of Dendrimer Cellular Entry and Trafficking.

Wang L, Yang L, Pan L, Kadasala NR, Xue L, Schuster RJ, Parker LL, Wei A, Tao WA.

J Am Chem Soc. 2015 Oct 14;137(40):12772-12775. doi: 10.1021/jacs.5b07875. Epub 2015 Oct 5.

17.

Multicolored, Tb³⁺-Based Antibody-Free Detection of Multiple Tyrosine Kinase Activities.

Lipchik AM, Perez M, Cui W, Parker LL.

Anal Chem. 2015 Aug 4;87(15):7555-8. doi: 10.1021/acs.analchem.5b02233. Epub 2015 Jul 24.

18.

KINATEST-ID: a pipeline to develop phosphorylation-dependent terbium sensitizing kinase assays.

Lipchik AM, Perez M, Bolton S, Dumrongprechachan V, Ouellette SB, Cui W, Parker LL.

J Am Chem Soc. 2015 Feb 25;137(7):2484-94. doi: 10.1021/ja507164a. Epub 2015 Feb 17.

19.

A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.

Cui W, Parker LL.

Chem Commun (Camb). 2015;51(2):362-5. doi: 10.1039/c4cc07453j. Epub 2014 Nov 18.

20.

A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain.

Gui J, Liu B, Cao G, Lipchik AM, Perez M, Dekan Z, Mobli M, Daly NL, Alewood PF, Parker LL, King GF, Zhou Y, Jordt SE, Nitabach MN.

Curr Biol. 2014 Mar 3;24(5):473-83. doi: 10.1016/j.cub.2014.01.013. Epub 2014 Feb 13.

21.

A quantitative proteomics-based competition binding assay to characterize pITAM-protein interactions.

Hu L, Yang L, Lipchik AM, Geahlen RL, Parker LL, Tao WA.

Anal Chem. 2013 May 21;85(10):5071-7. doi: 10.1021/ac400359t. Epub 2013 May 8.

22.

Fluorescence lifetime imaging of biosensor peptide phosphorylation in single live cells.

Damayanti NP, Parker LL, Irudayaraj JM.

Angew Chem Int Ed Engl. 2013 Apr 2;52(14):3931-4. doi: 10.1002/anie.201209303. Epub 2013 Feb 28. No abstract available.

23.

A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.

Yang TY, Eissler CL, Hall MC, Parker LL.

PLoS One. 2013;8(2):e56627. doi: 10.1371/journal.pone.0056627. Epub 2013 Feb 20.

24.

Time-resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitization.

Lipchik AM, Parker LL.

Anal Chem. 2013 Mar 5;85(5):2582-8. doi: 10.1021/ac3023422. Epub 2013 Feb 15.

25.

A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition.

Lipchik AM, Killins RL, Geahlen RL, Parker LL.

Biochemistry. 2012 Sep 25;51(38):7515-24. doi: 10.1021/bi300970h. Epub 2012 Sep 12.

26.

Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor.

Tang J, Wang JY, Parker LL.

Chembiochem. 2012 Mar 19;13(5):665-73. doi: 10.1002/cbic.201100763. Epub 2012 Feb 14.

27.

Akt2 inhibits the activation of NFAT in lymphocytes by modulating calcium release from intracellular stores.

Martin VA, Wang WH, Lipchik AM, Parker LL, He Y, Zhang S, Zhang ZY, Geahlen RL.

Cell Signal. 2012 May;24(5):1064-73. doi: 10.1016/j.cellsig.2012.01.001. Epub 2012 Jan 11.

28.

Cdc14 phosphatases preferentially dephosphorylate a subset of cyclin-dependent kinase (Cdk) sites containing phosphoserine.

Bremmer SC, Hall H, Martinez JS, Eissler CL, Hinrichsen TH, Rossie S, Parker LL, Hall MC, Charbonneau H.

J Biol Chem. 2012 Jan 13;287(3):1662-9. doi: 10.1074/jbc.M111.281105. Epub 2011 Nov 23.

29.

A general strategy for studying multisite protein phosphorylation using label-free selected reaction monitoring mass spectrometry.

Eissler CL, Bremmer SC, Martinez JS, Parker LL, Charbonneau H, Hall MC.

Anal Biochem. 2011 Nov 15;418(2):267-75. doi: 10.1016/j.ab.2011.07.015. Epub 2011 Jul 22.

30.

Peptide reporters of kinase activity in whole cell lysates.

Wu D, Sylvester JE, Parker LL, Zhou G, Kron SJ.

Biopolymers. 2010;94(4):475-86. doi: 10.1002/bip.21401. Review.

31.

A peptide biosensor for detecting intracellular Abl kinase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Placzek EA, Plebanek MP, Lipchik AM, Kidd SR, Parker LL.

Anal Biochem. 2010 Feb 1;397(1):73-8. doi: 10.1016/j.ab.2009.09.048. Epub 2009 Oct 7.

32.

Rationalization of the difference in lifetime of two covalent sialosyl-enzyme intermediates of Trypanosoma rangeli sialidase.

Parker LL, Chung YH, Margulis CJ, Jensen JH.

J Phys Chem B. 2008 Nov 13;112(45):14093-5. doi: 10.1021/jp804314x. Epub 2008 Oct 17.

PMID:
18925775
33.

Effects of acute alcohol consumption on ratings of attractiveness of facial stimuli: evidence of long-term encoding.

Parker LL, Penton-Voak IS, Attwood AS, Munafò MR.

Alcohol Alcohol. 2008 Nov-Dec;43(6):636-40. doi: 10.1093/alcalc/agn065. Epub 2008 Aug 6.

PMID:
18684808
34.

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Wu D, Mand MR, Veach DR, Parker LL, Clarkson B, Kron SJ.

Anal Biochem. 2008 Apr 1;375(1):18-26. doi: 10.1016/j.ab.2007.12.023. Epub 2007 Dec 25.

35.

Kinase activation in circulating cells: opportunities for biomarkers for diagnosis and therapeutic monitoring.

Parker LL, Kron SJ.

Expert Opin Med Diagn. 2008 Jan;2(1):33-46. doi: 10.1517/17530059.2.1.33.

PMID:
23485115
36.

Prestin-prestin and prestin-GLUT5 interactions in HEK293T cells.

Wu X, Currall B, Yamashita T, Parker LL, Hallworth R, Zuo J.

Dev Neurobiol. 2007 Mar;67(4):483-97.

37.

Overexpression of SK2 channels enhances efferent suppression of cochlear responses without enhancing noise resistance.

Maison SF, Parker LL, Young L, Adelman JP, Zuo J, Liberman MC.

J Neurophysiol. 2007 Apr;97(4):2930-6. Epub 2007 Jan 31.

38.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

39.

Photocleavable peptide hydrogel arrays for MALDI-TOF analysis of kinase activity.

Parker LL, Brueggemeier SB, Rhee WJ, Wu D, Kent SB, Kron SJ, Palecek SP.

Analyst. 2006 Oct;131(10):1097-104. Epub 2006 Jul 19.

PMID:
17003856
40.

Identification of 17 hearing impaired mouse strains in the TMGC ENU-mutagenesis screen.

Kermany MH, Parker LL, Guo YK, Miller D, Swanson DJ, Yoo TJ, Goldowitz D, Zuo J.

Hear Res. 2006 Oct;220(1-2):76-86. Epub 2006 Sep 1.

PMID:
16949226
41.

Control of the yeast cell cycle with a photocleavable alpha-factor analogue.

Parker LL, Kurutz JW, Kent SB, Kron SJ.

Angew Chem Int Ed Engl. 2006 Sep 25;45(38):6322-5. No abstract available.

42.

Cooperative hydrogen bonding effects are key determinants of backbone amide proton chemical shifts in proteins.

Parker LL, Houk AR, Jensen JH.

J Am Chem Soc. 2006 Aug 2;128(30):9863-72.

PMID:
16866544
43.

Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease: the use of public gene-targeted ES cell resources.

Parker LL, Gao J, Zuo J.

Brain Res. 2006 May 26;1091(1):235-42. Epub 2006 Apr 21.

PMID:
16630581
44.

Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.

Wu D, Nair-Gill E, Sher DA, Parker LL, Campbell JM, Siddiqui M, Stock W, Kron SJ.

Anal Biochem. 2005 Dec 1;347(1):67-76. Epub 2005 Sep 22.

45.

Optimizing thiophosphorylation in the presence of competing phosphorylation with MALDI-TOF-MS detection.

Parker LL, Schilling AB, Kron SJ, Kent SB.

J Proteome Res. 2005 Sep-Oct;4(5):1863-6.

46.

Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.

Powell DJ Jr, Parker LL, Rosenberg SA.

J Immunother. 2005 Jul-Aug;28(4):403-11.

47.

Synthesis of novel DNA cross-linking antitumour agents based on polyazamacrocycles.

Parker LL, Anderson FM, O'Hare CC, Lacy SM, Bingham JP, Robins DJ, Hartley JA.

Bioorg Med Chem. 2005 Apr 1;13(7):2389-95.

PMID:
15755641
48.

A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.

Parker LL, Lacy SM, Farrugia LJ, Evans C, Robins DJ, O'Hare CC, Hartley JA, Jaffar M, Stratford IJ.

J Med Chem. 2004 Nov 4;47(23):5683-9.

PMID:
15509167
49.

Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1.

Parker LL, Backstrom JR, Sanders-Bush E, Shieh BH.

J Biol Chem. 2003 Jun 13;278(24):21576-83. Epub 2003 Apr 7.

50.

Immunization against endogenous retroviral tumor-associated antigens.

Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P.

Cancer Res. 2001 Nov 1;61(21):7920-4.

Supplemental Content

Loading ...
Support Center